

# ASX Announcement



Medibio Limited – 15 November 2022

## MEDIBIO RECEIVES R&D TAX INCENTIVE REFUND

**Melbourne, Australia and Minneapolis, MN – 15 November 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF)**, is pleased to announce that it has received approximately \$938k through its Research & Development Tax Incentive Refund for the 2021/2022 financial year.

The Research and Development (R&D) Tax Incentive is the government's key mechanism to stimulate Australian industry's investment in R&D, encouraging companies to engage in R&D benefiting Australia, by providing a tax offset of up to 43.5% (refundable) for eligible R&D activities.

Medibio Chief Executive Officer, Dr Tom Young, said: *"This rebate will be applied to further developing the Company's technologies. We greatly appreciate the support of the Australian Government with this incentive, as Medibio advances towards the clinic."*

ENDS

*This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.*

### About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au).

### Medibio Investor Enquiries:

Medibio Investor Relations  
[investors@medibio.com.au](mailto:investors@medibio.com.au)  
+61 3 9692 7222